Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all group.
Defina M, Lazzarotto D, Guolo F, Minetto P, Fracchiolla NS, Giglio F, Forghieri F, Vitale A, Chiaretti S, Papayannidis C, Piccini M, Mulè A, Bocchia M, Leoncin M, Gurrieri C, Aprile L, Lunghi M, Bonifacio M, Pasciolla C, Cerrano M, Fumagalli M, Foà R, Candoni A. Defina M, et al. Among authors: minetto p. Leuk Res. 2022 Nov;122:106963. doi: 10.1016/j.leukres.2022.106963. Epub 2022 Sep 21. Leuk Res. 2022. PMID: 36155352 No abstract available.
Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression.
Miglino M, Colombo N, Grasso R, Marani C, Clavio M, Pica GM, Ballerini F, Ghiggi C, Minetto P, Guolo F, Carella AM, Gobbi M. Miglino M, et al. Among authors: minetto p. Leuk Lymphoma. 2012 Nov;53(11):2214-7. doi: 10.3109/10428194.2012.681658. Epub 2012 May 21. Leuk Lymphoma. 2012. PMID: 22475129
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives.
Guolo F, Minetto P, Clavio M, Miglino M, Lemoli RM, Gobbi M. Guolo F, et al. Among authors: minetto p. Biosci Trends. 2017 Mar 22;11(1):110-114. doi: 10.5582/bst.2016.01221. Epub 2017 Jan 24. Biosci Trends. 2017. PMID: 28123146 Free article.
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.
Minetto P, Guolo F, Clavio M, Kunkl A, Colombo N, Carminati E, Fugazza G, Matarese S, Guardo D, Ballerini F, Di Grazia C, Raiola AM, Cagnetta A, Cea M, Miglino M, Lemoli RM, Gobbi M. Minetto P, et al. Br J Haematol. 2019 Feb;184(3):457-460. doi: 10.1111/bjh.15106. Epub 2018 Jan 23. Br J Haematol. 2019. PMID: 29359798 Free article. No abstract available.
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach.
Guolo F, Minetto P, Clavio M, Miglino M, Colombo N, Cagnetta A, Cea M, Marcolin R, Todiere A, Ballerini F, Gobbi M, Lemoli RM. Guolo F, et al. Among authors: minetto p. Br J Haematol. 2019 Sep;186(6):e223-e225. doi: 10.1111/bjh.16116. Epub 2019 Jul 26. Br J Haematol. 2019. PMID: 31348524 Free article. No abstract available.
39 results